| Objective:This study aims to observe the clinical results of triptolide in treatment ofdiabetic nephropathy in type1and type2diabetic nephropathy.Method:Use a prospectiverandomized method to divide40cases of type2diabetic nephropathy patients who meetthe criteria for the diagnosis into two groups.20patients were classified into control groupwho were treated with Western medicine foundations treatment.20patients were classifiedinto treatment group who were treated with Western medicine foundation treatment andtriptolide. since the examination method and the patients of type1diabetic nephropathyless, only collect10patients who meet the diagnostic standard to divide into two group.5patients were classified into control group who were treated with Western medicinefoundations treatment.5patients were classified into treatment group who were treatedwith Western medicine foundation treatment and triptolide. Patients were observed thechange before and after treatment of24hPRO,mAlb,Ccr,Scr,BUN,TNF-α,Hs-CRP and soon. Results:(1)As a result of type1diabetic patients with nephropathy collected less,don’thave statistical significance.(2)1)The total clinical effective rate of treatment group is75%,which is better than that of control group with statisticatl(P<0.05).2)The treatmentgroup in reducing24hPRO,mAlb,TNF-α,Hs-CRP is better than the control group(P＜0.05),but in Ccr,Scr,BUN,there is no significant difference between the twogroup(P>0.05).3)The treatment group can significantly reduce FBG,PBG and HbA1c(P<0.05)..But there was no significant difference with control group in reducingFBG,PBG and HbA1c(P>0.05).4)There is no significant difference between the controlgroup in adjusting blood pressure and lipids(p>0.05). |
PDF Full Text Request